Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

migraine

- PMLiVE

Cystic fibrosis group pledges $58m to Pfizer discovery programme

Pharma company forms public-private partnership with Cystic Fibrosis Foundation

- PMLiVE

Pfizer’s arthritis hope Xeljanz gets US approval

Could present a major challenge to existing biologic treatments like Humira and Orencia

- PMLiVE

Pfizer helps fund biotech venture from former researchers at closed Kent facility

Ziarco headed by former Pfizer chief scientific officer, allergy and respiratory research, Mike Yeadon

- PMLiVE

More action needed to prevent AF-related strokes

Bayer-sponsored report says Europe is heading for a ‘stroke crisis’

- PMLiVE

GSK, Pfizer and Shionogi rewrite HIV joint venture terms

Comes ahead of first regulatory submissions for lead drug candidate dolutegravir

- PMLiVE

Pfizer’s Elvira Sanz named next president of Farmaindustria

Will lead Spanish pharma industry body for the new two years

- PMLiVE

The first public presentation of human Lipitor data

This month In 1994: The first public presentation of human Lipitor data

- PMLiVE

Pfizer pays $680m to buy ADHD drug developer NextWave

Portfolio includes once-daily Quillivant XR

New data backs Pfizer’s Eliquis in atrial fibrillation

Findings bode well for the drug's commercial prospects

- PMLiVE

India revokes Pfizer’s patent on Sutent

Loses patent protection for kidney cancer drug after Cipla and Natco challenge

Shionogi-ViiV to file HIV drug dolutegravir for approval

GSK, Pfizer and Shionogi joint venture completes phase III trials programme

FDA sets new date for Eliquis review in atrial fibrillation

US regulator had asked for more data from Pfizer and BMS

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links